Onconova Competitors

Delisted . USA . 
Stock . Onconova Therapeutics
ONTXDelisted Stock  USD 1.02  0.04  3.77%   
Onconova Therapeutics competes with Jaguar Animal, Ibio, GeoVax Labs, Ocugen, and Tonix Pharmaceuticals; as well as few others. The company conducts business under Pharmaceuticals sector and is part of Health Care industry. Analyzing Onconova Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Onconova Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Onconova Therapeutics competition on your existing holdings.
  
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Onconova Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
1.021.021.02
Details
Intrinsic
Valuation
LowRealHigh
0.950.951.12
Details
Naive
Forecast
LowNextHigh
1.041.041.04
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
1.001.031.06
Details

Onconova Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Onconova Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Onconova and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Onconova Therapeutics does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
PALI
+ 0.89
SONN
TNXP
+ 0.85
GOVX
OCGN
+ 0.8
GOVX
DFFN
+ 0.78
PALI
AEZS
+ 0.77
OCGN
DFFN
+ 0.77
SONN
  
High negative correlations   
AEZS
- 0.78
IBIO
OCGN
- 0.71
IBIO
GOVX
- 0.57
IBIO
DFFN
- 0.5
IBIO
SONN
- 0.49
IBIO
ADIL
- 0.37
JAGX

Risk-Adjusted Indicators

There is a big difference between Onconova Stock performing well and Onconova Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Onconova Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
JAGX  2.91 (0.25) 0.00 (0.24) 0.00 
 0.00 
 8.13 
(7.94)
 27.65 
IBIO  3.75  0.46  0.10  0.89  3.57 
(4.95)
 7.76 
(6.47)
 30.48 
GOVX  5.93 (1.14) 0.00 (0.52) 0.00 
 0.00 
 9.26 
(12.70)
 77.95 
OCGN  3.34 (0.63) 0.00 (0.19) 0.00 
 0.00 
 8.08 
(6.19)
 18.12 
TNXP  5.73 (0.92) 0.00 (0.14) 0.00 
 0.00 
 14.29 
(13.33)
 34.91 
SONN  4.81 (0.70) 0.00  2.52  0.00 
 0.00 
 12.31 
(9.79)
 37.58 
PALI  3.52 (0.50) 0.00 (1.92) 0.00 
 0.00 
 5.97 
(8.55)
 24.25 
ADIL  2.74  0.07 (0.01) 2.98  2.95 
(4.00)
 8.91 
(5.83)
 22.17 
DFFN  2.40 (0.43) 0.00  0.76  0.00 
 0.00 
 4.09 
(5.32)
 12.34 
AEZS  3.91 (0.15) 0.00  0.63  0.00 
 0.00 
 7.71 
(8.37)
 46.37 
All Fundamental Data

Onconova Therapeutics Competitive Analysis

The better you understand Onconova Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Onconova Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Onconova Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
ONTX JAGX IBIO GOVX OCGN TNXP SONN PALI ADIL DFFN
 3.77 
 1.02 
Onconova
 5.05 
 1.04 
Jaguar
 7.76 
 2.64 
Ibio
 9.26 
 2.95 
GeoVax
 1.11 
 0.91 
Ocugen
 5.00 
 0.19 
Tonix
 3.11 
 2.98 
Sonnet
 0.41 
 2.44 
Palisade
 0.98 
 1.01 
Adial
 5.48 
 3.27 
Diffusion
Market Volatility
(90 Days Market Risk)
Very steady
Very risky
Dangerous
Dangerous
Dangerous
Dangerous
Somewhat reliable
Relatively risky
Slightly risky
Very steady
Market Performance
(90 Days Performance)
Very Weak
Very Weak
OK
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
High
Quite High
Very High
Low
Very High
Very High
Very High
Very High
Dangerous
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Cautious Hold
Strong Sell
Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Not Rated
Current Ratio
7.43
1.02
1.48
9.51
7.21
12.05
1.1
2.59
5.32
11.59
Net Asset
22.68 T
50.76 M
28.73 M
9.28 M
64.55 M
154.46 M
5.43 M
14.05 M
4.74 M
22.64 M
Profit Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
EBITDA
(20.3 T)
(33.13 M)
(14.02 M)
(26.67 M)
(64.83 M)
(114.09 M)
(18.72 M)
(12.28 M)
(7 M)
(15.97 M)
Operating Margin
-89.28
-2.64
-19.48
-16.84
-11.67
-8.31
-219.69
N/A
N/A
N/A
Current Valuation
(4.56 M)
33.27 M
17.35 M
26.42 M
232.43 M
15.97 M
(907.92 K)
(3.95 M)
4.35 M
(6.02 M)
Price To Book
1.43
0.9
1.36
3.27
6.51
0.48
0.92
0.56
1.11
0.51
Retained Earnings
(482.63 T)
(308.25 M)
(313.85 M)
(104.36 M)
(286.17 M)
(600.66 M)
(110.24 M)
(121.51 M)
(68.8 M)
(145.6 M)
Current Asset
23.18 M
8.45 M
23.91 M
1.24 M
17.53 M
46.36 M
N/A
N/A
1.02 M
3.29 M
Beta
1.35
0.88
-3.37
3.11
3.77
2.08
1.05
1.33
1.3
1.76
Number Of Employees
16
49
16
17
65
103
12
9
4
13
Shares Outstanding
21 M
11.8 M
9.14 M
9.44 M
291.32 M
186.89 M
837.66 K
1.33 M
6.41 M
2.04 M
Cash Flow From Operations
(17.93 T)
(33.24 M)
(18.55 M)
(25.17 M)
(62.05 M)
(102 M)
(21.34 M)
(11.13 M)
(6.81 M)
(14.97 M)
Annual Yield
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Debt
N/A
37.09 M
4.46 M
3.52 M
6.94 M
9.81 M
203.91 K
369 K
653.08 K
67.89 K
Return On Equity
-0.84
-2.91
-0.84
-3.62
-1.03
-1.63
-2.65
-1.1
-3.21
-0.64
Z Score
-32.73
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
69.08
Return On Asset
-0.38
-0.35
-0.3
-1.34
-0.48
-0.52
-0.97
-0.59
-1.04
-0.38
Number Of Shares Shorted
20.7 K
332.32 K
307.8 K
301.02 K
50.65 M
7.67 M
66.23 K
43.11 K
78.88 K
2.54 K
Book Value Per Share
0.69
4.06
2.47
2.92
0.16
57.61
4.01
18.3
2.46
6.97
Current Liabilities
7.61 M
3.91 M
2.29 M
126.99 K
4.21 M
6.65 M
N/A
N/A
452.53 K
3.68 M
Total Asset
22.68 T
50.76 M
28.73 M
9.28 M
64.55 M
154.46 M
5.43 M
14.05 M
4.74 M
22.64 M
Debt To Equity
1.26
N/A
0.44
0.009
0.067
0.003
0.36
0.23
0.029
0.001
Short Ratio
0.19
1.12
1.46
0.35
16.43
0.35
1.44
0.29
0.65
0.29
Target Price
8.33
6.0
4.3
14.2
6.25
21.0
240.0
30.33
7.5
40.0
Shares Owned By Institutions
7.95
1.95
31.92
10.82
27.52
0.23
0.61
3.57
3.03
10.27
Market Capitalization
20.9 M
12.27 M
23.3 M
27.84 M
264.34 M
35.51 M
2.5 M
3.73 M
6.47 M
8.98 M
Price To Earning
-0.87
-0.96
-2.18
-1.25
-1.81
-0.69
N/A
0.16
-1.88
-0.6
Price To Earnings To Growth
N/A
-0.02
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Price To Sales
92.5
1.2
138.03
92.58
56.24
2.85
44.67
14.03
N/A
N/A
Net Income
(18.95 T)
(41.3 M)
(24.91 M)
(25.97 M)
(63.08 M)
(116.66 M)
(18.83 M)
(12.3 M)
(7 M)
(15.59 M)
Earnings Per Share
-0.96
20.2
-4.03
-8.39
-0.19
-80.39
-0.96
-13.26
-2.94
-7.11
Shares Owned By Insiders
0.77
12.02
0.14
0.52
1.39
0.16
4.22
1.88
1.79
0.23
Revenue
226 B
9.76 M
225 K
N/A
6.04 M
7.77 M
147.81 K
250 K
N/A
N/A
Working Capital
31.3 M
(8.02 M)
11.83 M
4.37 M
25.88 M
28.88 M
(786.37 K)
10.74 M
2.99 M
20.22 M
Cash And Equivalents
46.53 M
9.01 M
33.52 M
30.9 M
101.6 M
145.48 M
5.22 M
5 M
9.16 M
25.86 M
Cash Per Share
2.23
0.08
3.72
1.25
0.46
3.38
1.21
0.23
0.35
12.68
Gross Profit
226 K
2 M
2.17 M
81.53 K
(49.76 M)
N/A
(21.09 M)
N/A
N/A
N/A
Day Typical Price
1.03
1.02
2.63
2.89
0.91
0.2
2.95
2.5
1.01
3.22
Accumulation Distribution
0.0561
0.0857
0.14
0.12
0.043
0.0952
0.04
0.13
0.0294
0.0549
Market Facilitation Index
0.06
0.09
0.39
0.37
0.04
0.02
0.12
0.35
0.03
0.18
Daily Balance Of Power
(0.67)
0.5556
0.4872
0.6757
0.25
(0.50)
0.75
0.0286
(0.33)
0.9444
Period Momentum Indicator
(0.04)
0.05
0.19
0.25
0.01
(0.01)
0.09
0.01
(0.01)
0.17
Rate Of Daily Change
0.96
1.05
1.08
1.09
1.01
0.95
1.03
1.0
0.99
1.05
Day Median Price
1.04
1.0
2.63
2.87
0.91
0.2
2.94
2.53
1.0
3.19
Price Action Indicator
(0.04)
0.06
0.11
0.21
0.005
(0.01)
0.085
(0.08)
N/A
0.17
Relative Strength Index
13.16
7.48
53.92
38.1
53.41
50.98
50.51
36.5
58.71
22.85
Coefficient Of Variation
1047.88
(2,931)
949.24
(1,134)
(1,129)
(1,721)
(945.38)
(1,056)
5153.91
(595.23)
Mean Deviation
4.73
2.91
3.75
5.93
3.34
5.73
4.81
3.52
2.74
2.4
Jensen Alpha
1.01
(0.25)
0.4553
(1.14)
(0.63)
(0.92)
(0.70)
(0.50)
0.0658
(0.43)
Total Risk Alpha
(0.56)
(0.88)
(0.28)
(2.56)
(1.04)
(1.81)
(1.81)
(1.24)
(0.57)
(0.99)
Sortino Ratio
0.1501
N/A
0.1007
N/A
N/A
N/A
N/A
N/A
(0.01)
N/A
Downside Variance
22.97
N/A
16.3
N/A
N/A
N/A
N/A
N/A
12.32
N/A
Standard Deviation
8.91
4.55
5.1
10.39
4.18
8.37
6.84
4.88
4.05
3.0
Kurtosis
23.25
4.36
3.22
19.25
(0.09)
1.71
1.86
3.24
2.76
(0.33)
Potential Upside
7.69
8.13
7.76
9.26
8.08
14.29
12.31
5.97
8.91
4.09
Treynor Ratio
(0.59)
(0.24)
0.8853
(0.52)
(0.19)
(0.14)
2.52
(1.92)
2.98
0.759
Maximum Drawdown
66.73
27.65
30.48
77.95
18.12
34.91
37.58
24.25
22.17
12.34
Variance
79.36
20.66
26.01
107.95
17.47
69.97
46.82
23.85
16.39
8.98
Market Risk Adjusted Performance
(0.58)
(0.23)
0.8953
(0.51)
(0.18)
(0.13)
2.53
(1.91)
2.99
0.769
Risk Adjusted Performance
0.0823
(0.02)
0.0893
(0.06)
(0.06)
(0.04)
(0.07)
(0.06)
0.023
(0.12)
Skewness
4.15
1.22
1.16
3.43
0.58
0.2201
0.4097
0.5171
1.13
(0.24)
Semi Deviation
4.35
N/A
3.57
N/A
N/A
N/A
N/A
N/A
2.95
N/A
Information Ratio
0.0808
(0.06)
0.0797
(0.10)
(0.12)
(0.07)
(0.12)
(0.12)
(0.01)
(0.21)
Value At Risk
(8.33)
(7.94)
(6.47)
(12.70)
(6.19)
(13.33)
(9.79)
(8.55)
(5.83)
(5.32)
Expected Short fall
(5.89)
N/A
(4.95)
N/A
N/A
N/A
N/A
N/A
(4.00)
N/A
Downside Deviation
4.79
N/A
4.04
N/A
N/A
N/A
N/A
N/A
3.51
N/A
Semi Variance
18.94
N/A
12.75
N/A
N/A
N/A
N/A
N/A
8.72
N/A

Onconova Therapeutics Competition Performance Charts

Five steps to successful analysis of Onconova Therapeutics Competition

Onconova Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Onconova Therapeutics in relation to its competition. Onconova Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Onconova Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Onconova Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Onconova Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Onconova Therapeutics position

In addition to having Onconova Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Cleaning Thematic Idea Now

Cleaning
Cleaning Theme
Compnanies producing and distributing cleaning products, supplies, and accessories. The Cleaning theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cleaning Theme or any other thematic opportunities.
View All  Next Launch
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.

Other Consideration for investing in Onconova Stock

If you are still planning to invest in Onconova Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Onconova Therapeutics' history and understand the potential risks before investing.
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY